Psoriasis: dysregulation of innate immunity
- PMID: 15948970
- DOI: 10.1111/j.1365-2133.2005.06645.x
Psoriasis: dysregulation of innate immunity
Abstract
The current understanding of the function of natural killer (NK) T cells in innate immunity and their potential to control acquired specific immunity, as well as the remarkable efficacy of antitumour necrosis factor-alpha biological treatments in psoriasis, forces us to refine the current T-cell hypothesis of psoriasis pathogenesis, and to give credit to the role of innate immunity. Psoriasis might be envisioned to be a genetically determined triggered state of otherwise dormant innate immunity. This aggravated state of innate immunity is represented by the activity of NK T cells, dendritic cells, neutrophils and keratinocytes, leading to the recruitment and activation of preferentially type 1 T cells, possibly in an antigen-independent way. Keratinocytes in psoriasis then are sensitive to the effects of T-cell activation and cytokine production, interferon (IFN)-gamma, by responding with psoriasiform hyperplasia. The chronic inflammation of psoriatic lesions suggests that this might be due to a deficiency in downregulation processes (e.g. a defect in the regulatory T-cell repertoire) and/or the persistence of an unknown trigger resulting in an exaggerated innate immune response.
Similar articles
-
Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.Br J Dermatol. 2007 Aug;157(2):249-58. doi: 10.1111/j.1365-2133.2007.07945.x. Epub 2007 May 8. Br J Dermatol. 2007. PMID: 17489975
-
Innate and adaptive immunity and the pathophysiology of psoriasis.J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S67-80. doi: 10.1016/j.jaad.2005.10.057. J Am Acad Dermatol. 2006. PMID: 16488332 Review.
-
Immunopathogenesis of psoriasis: focus on natural killer T cells.J Eur Acad Dermatol Venereol. 2009 Oct;23(10):1123-7. doi: 10.1111/j.1468-3083.2009.03292.x. Epub 2009 Apr 30. J Eur Acad Dermatol Venereol. 2009. PMID: 19453772 Review.
-
The immunopathogenesis of psoriasis.Dermatol Clin. 2015 Jan;33(1):13-23. doi: 10.1016/j.det.2014.09.002. Dermatol Clin. 2015. PMID: 25412780 Review.
-
Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha.Immunology. 2006 Jan;117(1):38-46. doi: 10.1111/j.1365-2567.2005.02261.x. Immunology. 2006. PMID: 16423039 Free PMC article.
Cited by
-
MRSA and Skin Infections in Psoriatic Patients: Therapeutic Options and New Perspectives.Antibiotics (Basel). 2022 Oct 28;11(11):1504. doi: 10.3390/antibiotics11111504. Antibiotics (Basel). 2022. PMID: 36358159 Free PMC article.
-
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.Br J Pharmacol. 2010 Feb;159(4):842-55. doi: 10.1111/j.1476-5381.2009.00559.x. Epub 2009 Dec 24. Br J Pharmacol. 2010. PMID: 20050849 Free PMC article.
-
NK cells and psoriasis.J Biomed Biotechnol. 2011;2011:248317. doi: 10.1155/2011/248317. Epub 2011 May 26. J Biomed Biotechnol. 2011. PMID: 21687543 Free PMC article. Review.
-
Cellular dissection of psoriasis for transcriptome analyses and the post-GWAS era.BMC Med Genomics. 2014 May 22;7:27. doi: 10.1186/1755-8794-7-27. BMC Med Genomics. 2014. PMID: 24885462 Free PMC article.
-
Treatments in psoriasis: from standard pharmacotherapy to nanotechnology therapy.Postepy Dermatol Alergol. 2022 Jun;39(3):460-471. doi: 10.5114/ada.2021.108445. Epub 2021 Aug 16. Postepy Dermatol Alergol. 2022. PMID: 35950130 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical